Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

University of Health Sciences Antigua gears up for psilocybin research

By Brian Buntz | November 10, 2022

UHSAThe University of Health Sciences Antigua (UHSA) has partnered with Toronto-based Revive Therapeutics (CSE:RVV, USA:RVVTF) to research the potential of psilocybin to help those with addiction. Revive’s focus has increased following its 2020 acquisition of Psilocin Pharma Corp.

University of Health Sciences Antigua is currently in the process of obtaining permits to import psilocybin for translational research, according to Dr. Manuel Flores, a professor at the University of Health Sciences Antigua. “We’re in the preliminary phases right now,” he said.

The university intends to focus on exploring the “lighter side of the benefits of psilocybin since the island is still new to it,” said Dr. Adedayo Akande, president of UHSA. “We decided to do a proposal study for investigating the therapeutic potential of psilocybin for alcohol dependence,” Akande notes.

Dr. Adedayo Akande

Dr. Adedayo Akande

Akande anticipates that the study will commence in 2023. After the initial research, the university could investigate the potential of psilocybin for other types of addiction and mood disorders.

Akande foresees that its research into psilocybin and potentially other psychedelics could ultimately inform its medical school curriculum in the coming years. “One of the main reasons we established this agreement with Revive is because we are a medical school,” Akande said. “We truly believe that natural psychedelic products are the future of medicine, and the reality is that psychedelics are not typically taught in medical school.”

Currently, psychedelics continue a gradual march toward legitimization, following a path similar to cannabis. However, research into psychedelics such as psilocybin, DMT and 5-MeO-DMT could help physicians of the future contextualize the expanded use of those compounds. “At the end of the day, future physicians need to have this knowledge because whether they like it or not, this is the direction medicine is headed,” Akande said.

While the active ingredient in cannabis, THC, remains a Schedule 1 compound, research on it and other cannabinoids has ramped up as many states have legalized medical or recreational marijuana.

Akande adds that former professional boxer Mike Tyson played a role in spurring his interest in psychedelics. Tyson’s organization visited UHSA during a visit to Antigua in 2019. “That meeting kind of sparked everything,” Akande said. “We thought, ‘You know what? There’s more to this. Let’s do some more research on this.'”

Dr. Manuel Flores

Dr. Manuel Flores

Eventually, Akande reached out to Revive Therapeutics. “I saw what they were doing in the space and liked the research that came out of that company,” he said. “They wanted to see how they could partner with a medical institution, and so a partnership was born from there.”

In addition to research, University of Health Sciences Antigua could potentially establish a psychedelic actual therapy center using Revive products.

Akande stresses that the university will take a conservative approach to researching psilocybin and potentially other psychedelic compounds. “In other words, you’re not going to be taking a psychedelic and then wake up a couple of hours later talking to a sea turtle on the beach,” he joked.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: UHSA, University of Health Sciences Antigua
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE